News
BGNE
162.54
-0.45%
-0.73
BeiGene (BGNE) Shares Cross Above 200 DMA
NASDAQ · 1d ago
Weekly Report: what happened at BGNE last week (0715-0719)?
Weekly Report · 4d ago
Executive reshuffles: Otis Worldwide, HSBC and Rockwell Automation in focus
Executive reshuffles: Otis Worldwide, HSBC and Rockwell Automation in focus. Several Wall Street executives stepped up for new roles as part of leadership reshuffling. Some companies added new positions to steer growth prospects such as Otis worldwide, HSBC, ROK and Glencore.
Seeking Alpha · 07/19 18:40
BeiGene Announces New CFO Appointment and Senior Advisor Transition
TipRanks · 07/18 10:58
BeiGene names Aaron Rosenberg as CFO
Healthcare BeiGene names Aaron Rosenberg as CFO. Rosenberg was most recently senior vice president and corporate treasurer of Merck from 2021. BeiGene, Ltd. Said it has appointed Aaron Rosenberg to the role effective July 22. Wang stepped down from the role to pursue external opportunities.
Seeking Alpha · 07/18 10:38
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
Aaron Rosenberg will succeed Julia Wang as Chief Financial Officer of BeiGene. Mr. Rosenberg is a global finance executive with more than 20 years of experience at Merck & Co. He was most recently Senior Vice President and Corporate Treasurer of Merck. BeiGene is a top 15 global oncology company.
Barchart · 07/18 05:30
Weekly Report: what happened at BGNE last week (0708-0712)?
Weekly Report · 07/15 09:04
With 47% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns
Institutional investors own 47% of BeiGene, Ltd. (NASDAQ:BGNE) The company is owned by institutions and the top 5% of the company have control of more than half of the business. The top 5 shareholders of Bei Gene have a stake in the company worth US$736m. High institutional ownership implies BeiGene's stock price is sensitive to their trading actions. The company's biggest shareholder is Amgen Inc., with a ownership of 18%. BeiGene is a good investment for those who want to see how the company will grow in the future. It's worth looking at the insider purchasing of shares in BeiGene.
Simply Wall St · 07/12 11:20
BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A Securities
Dow Jones · 07/09 17:30
BeiGene Is Maintained at Neutral by B of A Securities
Dow Jones · 07/09 17:30
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
Benzinga · 07/09 17:20
Zymeworks: A Somewhat Complicated Story
Zymeworks Inc. Is a Vancouver-based oncology-focused clinical-stage biopharma firm. The company's lead candidate, zanidatamab, could have its first FDA approval in hand before the end of 2024. Zymeworks has significant partnership deals with Jazz Pharmaceuticals and BeiGene, Ltd. We update our analysis of the company in a follow-up article.
Seeking Alpha · 07/09 16:12
BeiGene Analysis: Hold Rating Amidst Mixed Drug Sales Performance and Market Competition
TipRanks · 07/09 10:36
Weekly Report: what happened at BGNE last week (0701-0705)?
Weekly Report · 07/08 09:04
Weekly Report: what happened at BGNE last week (0624-0628)?
Weekly Report · 07/01 09:05
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
Walgreens Boots Alliance, Inc. Shares tumbled 24.12% in the last week. The company reported mixed Q3 earnings and lowered 2024 guidance below consensus estimates. Floor & Decor Holdings and Moderna were the ten large-cap stocks worst performers. JD.Com stock fell 8.89% after rules to curb investments in Chinese technology.
Benzinga · 06/30 18:21
Add Up The Parts: FBT Could Be Worth $198
NASDAQ · 06/27 10:40
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
NASDAQ · 06/25 08:06
Beigene Ltd: Report of proposed sale of securities
Press release · 06/24 23:09
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
NASDAQ · 06/24 11:32
More
Webull provides a variety of real-time BGNE stock news. You can receive the latest news about Beigene Ltd through multiple platforms. This information may help you make smarter investment decisions.
About BGNE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.